1. The compositions are pharmaceutically acceptable injectable formulations which include an active component in a pharmaceutically acceptable carrier.

2. Pharmaceutically active insulin receptor-modulating molecules

3. Disclosed is a pharmaceutical composition comprising tranilast or a pharmaceutically acceptable salt thereof and allopurinol or a pharmaceutically acceptable salt thereof, wherein the amount by weight of said allopurinol or pharmaceutically acceptable salt thereof in said composition is greater than the amount by weight of said tranilast or pharmaceutically acceptable salt thereof in said composition.

4. Therefore, the acid addition salt can be useful as a pharmaceutically acceptable salt.

5. Pharmaceutical dosage forms comprising ecopipam free base or pharmaceutically acceptable salts thereof

6. Triazanonane derivative or pharmaceutically acceptable salt thereof for enhanced fluorine-18 labeling

7. Compounds of formula (I) and the pharmaceutically acceptable acid addition salts thereof, wherein R¿1?

8. Process for the preparation of pharmaceutically acceptable salts of (ss-rs)-s-adenosyl-l-methionine

9. The invention also discloses the preparation process and use of the toosendanin derivative having formula (II) and its pharmaceutically acceptable salts, the toosendanin derivative and its pharmaceutically acceptable salts have good treatment effects for botulinicum Antitoxinum animals.

10. The base may additionally comprise an acid sensitive or an alkali-sensitive pharmaceutically active substance.

11. Specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

12. Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient

13. Pharmaceutical composition capable of readily controlling dissolution pattern of lacosamide or pharmaceutically acceptable salt thereof

14. The invention also provides pharmaceutically acceptable compositions of therapeutically effective amounts of furin endoprotease inhibitors.

15. Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component

16. Basidiomycete fungi are an attractive resource for biologically active natural products for use in pharmaceutically relevant compounds

17. Novel method for the synthesis of ivabradine and the addition salts thereof with a pharmaceutically acceptable acid

18. Claimed are compound srepresented by Formula II, its enantiomers, diastereoisomers, tautomers, or a pharmaceutically acceptable salt thereof.

19. The present invention relates to a 2-ethoxy benzoic acid derivative and a pharmaceutically tolerable salt thereof.

20. The present product can be used as material for the preparation of pharmaceutically acceptable pharmaceutical preparations.

21. Specifically disclosed is a compound represented by formula (1) or a pharmaceutically acceptable salt thereof.

22. Cyanoguanidine compounds of Formula (I) and their pharmaceutically acceptable acid addition salts where R¿1?

23. Both therapeutic agents and diagnostic agents can be used as pharmaceutically active substances for encapsulation.

24. Specifically provided is a phenyltriazole derivative represented by formula (I) or a pharmaceutically acceptable salt thereof.

25. The present invention relates to compounds of formula 1: and pharmaceutically acceptable acid addition sails thereof.

26. Within the cell culture chamber, the pharmaceutically active compound may be absorbed and transported by a cell monolayer.

27. Composition for preventing hair loss or promoting hair growth, containing oleanolic acid derivative and pharmaceutically acceptable salt thereof

28. Composition for preventing and treating asthma, containing benzofuran-based compound or pharmaceutically acceptable salt thereof as active ingredient

29. If desired, additional antimicrobial or other pharmaceutically active agents can also be incorporated into the hydrogel structure.

30. A method for manufacturing an injectable preparation of a pharmaceutically active agent for storage in the injection cartridge.

31. The present invention relates to new medical uses for ethylamino benzoic acid derivatives or pharmaceutically acceptable salts thereof.

32. Pharmaceutical composition for treatment of asthma containing 4-phenylbutyric acids or pharmaceutically acceptable salts thereof as active ingredient

33. Pharmaceutical composition for preventing or treating optic neuromyelitis comprising glycyrrhizic acid or pharmaceutically acceptable salt thereof as an active ingredient

34. Provided are: a dry syrup comprising a pharmaceutically active substance, starch and a thixotropic thickener; and a production method therefor.

35. The present invention relates to a matrix type pharmaceutical composition containing lacosamide, which is an active ingredient, or a pharmaceutically acceptable salt thereof.

36. The present invention relates to a C-kit activity inhibitor comprising carnosic acid, a derivative thereof or a pharmaceutically acceptable salt thereof.

37. The present invention relates to a skin irritation alleviation agent comprising carnosic acid, a derivative thereof or a pharmaceutically acceptable salt thereof.

38. A pharmaceutical formulation comprising:(1) a therapeutically effective amount of active nasal peptide, its pharmaceutically acceptable salt or its peptidic fragment; and (2) the absorbefacient and stabilizer THAM [tris(hydroxymethyl) aminomethane); in a pharmaceutically acceptable, aqueous liquid diluent or carrier, said formulation being in a form suitable for nasal administration.

39. The present invention relates to a novel adenine derivative and a pharmaceutical use thereof and, more specifically, to a novel adenine derivative having a structure of chemical formula 1 or a pharmaceutically acceptable salt thereof and to a composition for preventing or treating degenerative brain disease, the composition containing the novel adenine derivative or the pharmaceutically acceptable salt thereof.

40. The present invention also relates to a whitening composition or anti-ageing composition comprising a carnosic acid derivative or a pharmaceutically acceptable salt thereof.

41. Prostaglandin F2α (PGF2α in prostanoid nomenclature), pharmaceutically termed dinoprost (INN), is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.

42. The present invention relates to a novel benzamide compound functioning as an inverse agonist or an antagonist of a cannabinoid receptor (CB1), or pharmaceutically acceptable salts thereof.

43. A lidocaine-containing Cataplasm comprising a backing layer and an adhesive agent (plaster) layer laminated on the surface of the backing layer, wherein the adhesive agent (plaster) layer contains at least one component selected from the group consisting of lidocaine and pharmaceutically acceptable salts thereof, the total content of lidocaine and the pharmaceutically acceptable salts thereof

44. Novel disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient

45. The present invention relates to a pharmaceutical composition that enables easy control of a release pattern of galantamine or pharmaceutically acceptable salts thereof as an active ingredient.

46. The invention concerns the use of riluzole or one of its pharmaceutically acceptable salts for preventing and/or treating acoustic traumas and, in particular, different types of deafness and tinnitus.

47. Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR').

48. The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description.

49. According to the present invention, there are provided ethacrynic acid, a transglutaminase inhibitor comprising active components of a pharmaceutically acceptable salt of ethacrynic acid and a transglutaminase inhibition method.

50. The subject invention relates to methods for sebum control and treatment of acne in mammalian skin and scalp comprising administration of hesperetin, having structure (I) or a pharmaceutically acceptable salt thereof.

51. A high purity extract composition comprising withanolide glycosides, oligosaccharides, withanolide aglycones and a minimum level of polysaccharides, and a pharmaceutically, veterinary or nutritionally acceptable carrier(s) is disclosed.

52. Isoquinoline-5-carboxamide derivative, expressed by chemical formula 1, and pharmaceutically acceptable salts, isomers, hydrates, and compounds selected from solvates thereof are useful in preventing or treating diseases with abnormal cell growth.

53. More specifically, the present invention relates to a pharmaceutical composition capable of readily controlling the dissolution pattern of an effective amount of lacosamide or a pharmaceutically acceptable salt thereof.

54. Novel di-substituted phenoxyacetyl-based compound or pharmaceutically acceptable salt thereof, production method for same and pharmaceutical composition for suppressing multiple drug resistance comprising same as an active ingredient

55. A pharmaceutical formulation comprising an anti-obesity agent, such as sibutramine, and at least one acidulant, such as fumaric acid, together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

56. The present invention relates to a pharmaceutical composition or a functional health food containing a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease.

57. Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6&Agr;, R6B and R8 are as defined in the specification.

58. The composition includes, as an active ingredient, a PPAR$g(g) and/or a RXR agonist which upregulates monocyte/m$g(f) CD36 in admixture with a pharmaceutically acceptable carrier, excipient or diluent.

59. (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition containing same as active ingredients for the diagnosis or treatment of neurodegenerative brain diseases

60. The present invention relates to a composition for improving sexual function, comprising, as an active ingredient, at least one compound selected from a group consisting of arginine derivatives or the pharmaceutically acceptable salts thereof.

61. The methods described herein provide reduction of intraocular pressure by administering a sustained release formulation including latanoprost and a pharmaceutically acceptable vehicle and administering an eye drop adjunctive composition to the eye of a patient.

62. A heterocyclic substituted Acardite derivate and use thereof namely compounds in the general formula (1) or the general formula (2) or pharmaceutically acceptable salts thereof, wherein A is monosubstituted or polysubstituted quinoline, isoquinoline, quinazoline, pyrrole, pyrimidine.

63. The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as &agr;1a/&agr;1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms.

64. The present invention relates to a pharmaceutical composition for preventing or treating gastroesophageal reflux disease and to a food composition for preventing or treating gastroesophageal flux disease, which contain chlorogenic acid, the pharmaceutically acceptable salts thereof, or derivatives thereof.

65. The invention concerns a carbon dioxide absorbent for use in anaesthesiology, in which the absorbent comprises at least one pharmaceutically acceptable hydroxide essentially free of sodium and/or potassium hydroxide and a carbon dioxide absorbingly effective amount of a compatible humectant.

66. The present invention relates to a pharmaceutical composition and functional health food containing 3-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating diabetes.

67. The present invention relates to a novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition with an inhibitory activity against Raf kinase, containing the same as an active ingredient.

68. More particularly, the present invention relates to an oral preparation having an enteric coating, which comprises zoledronic acid and the pharmaceutically acceptable salts thereof, and which has a core, the pH level of which is 3.5 to 7.

69. The invention relates to treatment of HIV in a subject with acyclovir or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, comprising the step of identifying the subject as possessing a herpes virus infection capable of converting acyclovir into acyclovir triphosphate.

70. In addition, the present invention relates to an antibiotic medical compound having the novel oxazolidinone derivative of the chemical formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, and a pharmaceutically permitted salt thereof, as active ingredients.

71. Purine compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases.

72. Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases.

73. Disclosed are a 2,4,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient.

74. Ethylidene hydrazidecarboxamide derivatives of formula (I) or pharmaceutically acceptable salts, hydrate or solvation thereof, methods for their preparation, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor.

75. The present invention relates to 4-[5-Methoxy-6-(2-methyl-6-[l,2,4]triazol-l-yl-pyridin-3- ylamino)-pyrimidin-4-yloxy]-piperidine-l -carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism.

76. Use of at least one phenylethanolaminotetraline of general formula (I): wherein A represents a (CI-C4)alkylene group, and R is hydrogen or a (CI-C4)alkyl group, or one of its pharmaceutically acceptable salts, for the preparation of a drug for treating anxiety disorders.

77. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

78. A compound of the formula (I) or a pharmaceutically acceptable s alt thereof: [wherein X is CH2, O or S, R1 is the moiety represented by the formula (II), etc.: [wherein R3 is lower alkyl, etc., m is integer of 1 to 3], R2 is hydrogen, etc.].

79. Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases.

80. Disclosed is the use of active substances known from human medicine for treating gout in order to pharmaceutically treat equine laminitis, especially the use of a preparation containing at least allopurinol and/or hydrocortisone and/or powdered opium and/or prednisolone and/or prednisone.